Biogen (BIIB) PT Lowered to $259 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $254.46 --0%
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 33 | New: 6
Rating Summary:
31 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 33 | New: 6
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $259.00 (from $263.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $300 at Guggenheim
- Scotts Miracle-Gro (SMG) PT Lowered to $67 at JPMorgan
- Procore Technologies, Inc (PCOR) PT Raised to $70 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
